www.janssencovid19vaccine.com Open in urlscan Pro
2606:4700::6812:1c80 Public Scan

Back to summary

Submitted URL:
https://janssencovid-19vaccine.com/
Effective URL:
https://www.janssencovid19vaccine.com/
Submission: On March 11 via api (March 11th 2023, 6:50:07 am UTC) from JP — Scanned from JP

Form analysis
1 forms found in the DOM

POST #

<form class="acsb-form" data-acsb-search="form" enctype="multipart/form-data" action="#" method="POST"> <input type="text" tabindex="0" name="acsb_search" autocomplete="off" placeholder="Unclear content? Search in dictionary..."
    aria-label="Unclear content? Search in dictionary..."> <i class="acsbi-search"></i> <i class="acsbi-chevron_down"></i> </form>

Text Content

Use Website In a Screen-Reader Mode
Skip to Content
↵ENTER
Skip to Menu
↵ENTER
Skip to Footer
↵ENTER

FDA EUA Letter EUA Fact Sheet for HCPs EUA Fact Sheet for Recipients &
Caregivers
Janssen.com
Janssen.com
FDA EUA Letter EUA Fact Sheet for HCPs EUA Fact Sheet for Recipients &
Caregivers

Janssen Infectious Diseases and Vaccines is committed to providing critical
updates and education related to COVID-19 and the Emergency Use Authorization of
the Janssen COVID-19 Vaccine. Janssen, in close collaboration with the FDA,
frequently updates Fact Sheets and guidance on the utilization of the Janssen
COVID-19 Vaccine.

This site has been optimized to provide the most up-to-date information with
links to resources.

JOHNSON & JOHNSON’S JANSSEN COVID-19 VACCINE: AUTHORIZED FOR EMERGENCY USE

The Janssen COVID-19 Vaccine has not been approved or licensed by the U.S. Food
and Drug Administration (FDA), but has been authorized by FDA through an
Emergency Use Authorization (EUA) for active immunization to prevent Coronavirus
Disease 2019 (COVID-19) in individuals 18 years of age and older for whom other
FDA-authorized or approved COVID-19 vaccines are not accessible or clinically
appropriate, and in individuals 18 years of age and older who elect to receive
the Janssen COVID-19 Vaccine because they would otherwise not receive a COVID-19
vaccine. The emergency use of this product is authorized only for the duration
of the declaration that circumstances exist justifying the authorization of the
emergency use of the medical product under Section 564(b)(1) of the FD&C Act,
unless the declaration is terminated or authorization revoked sooner.

FDA EUA Letter for the Janssen COVID-19 Vaccine

EUA FACT SHEET AND FULL EUA PRESCRIBING INFORMATION FOR VACCINATION PROVIDERS

EUA FACT SHEET FOR VACCINE RECIPIENTS AND CAREGIVERS

* FDA EUA Letter

To view the FDA EUA letter, please see:

Download
* EUA Fact Sheet and Full EUA Prescribing Information for Vaccination Providers

If you are a vaccination provider, please find EUA Fact Sheet and full EUA
Prescribing Information here:

Download
* EUA Fact Sheet for Vaccine Recipients and Caregivers

If you are a vaccine recipient or caregiver, please find EUA Fact Sheet for
Vaccine Recipients and Caregivers here:

Download

Reporting Vaccine Adverse Events

It is MANDATORY for vaccination providers to report to the Vaccine Adverse Event
Reporting System (VAERS) all vaccine administration errors, all serious adverse
events, cases of Multisystem Inflammatory Syndrome (MIS) in adults, and
hospitalized or fatal cases of COVID-19 following vaccination with the Janssen
COVID-19 Vaccine. To the extent feasible, provide a copy of the VAERS form to
Janssen Biotech, Inc.

Visit VAERS for more information and to report adverse events
* If you are unable to submit this form electronically, you may fax it to VAERS
at 1-877-721-0366. If you need additional help submitting a report, you may
call the VAERS toll-free information line at 1-800-822-79671-800-822-7967 or
send an email to info@vaers.org
or

* Contact Janssen Biotech, Inc. at:

US Toll Free: 1-800-565-40081-800-565-4008
US Toll: 1-908-455-99221-908-455-9922

Expiry Dates

Learn more about expiration tracking and how to check the expiry of the Janssen
COVID-19 Vaccine lots that you have received.

Go to Vaxcheck.jnj
Coronavirus Education

Get more information about the coronavirus.

CDC: COVID-19 Website Johns Hopkins Coronavirus Resource Center
COVID-19 Vaccine Information and Guidelines

Visit the Centers for Disease Control and Prevention (CDC) and National
Institutes of Health (NIH) websites for resources and guidelines.

ACIP Recommendations Information From NIH CDC's Morbidity and Mortality Weekly
Report for COVID-19

ENSURING THE AUTHENTICITY OF JOHNSON & JOHNSON'S JANSSEN COVID-19 VACCINE

Johnson & Johnson and Janssen Pharmaceuticals are committed to identifying and
mitigating the risks of counterfeit healthcare products. Information regarding
how we address counterfeiting can be found at healthforhumanityreport.jnj.com

The Janssen COVID-19 Vaccine is to be administered intramuscularly by a
healthcare professional.

An authentic Janssen COVID-19 Vaccine includes the Janssen name and logo on the
carton. The Janssen COVID-19 Vaccine is supplied in multi-dose vials. The vial
stoppers are not made with natural rubber latex.

The Janssen COVID-19 Vaccine is never sold online and is distributed only
through government channels. Janssen cannot verify the authenticity of products
acquired outside of the legitimate supply chain. If you suspect the Janssen
COVID-19 Vaccine you have may be counterfeit, contact us at
1-800-565-40081-800-565-4008 (US Toll Free) or 1-908-455-9922 1-908-455-9922 (US
Toll).

COVID-19=coronavirus disease 2019; EUA=Emergency Use Authorization; FD&C
Act=Federal Food, Drug, and Cosmetic Act.

SELECT IMPORTANT SAFETY INFORMATION

WARNING: THROMBOSIS WITH THROMBOCYTOPENIA SYNDROME

The Janssen COVID-19 Vaccine can cause thrombosis with thrombocytopenia syndrome
(TTS) which may be life-threatening.

TTS may involve thrombosis at unusual locations for a thrombus (i.e., cerebral
vein, visceral artery or vein, extremity artery, central artery or vein) or in
an extremity vein or pulmonary artery.

Among reported cases of TTS following administration of the Janssen COVID-19
Vaccine, symptoms began approximately one to two weeks after vaccination.

Instruct Janssen COVID-19 Vaccine recipients to seek immediate medical attention
for shortness of breath, chest pain, leg swelling, persistent abdominal pain,
neurological symptoms (including severe or persistent headaches or blurred
vision), or petechiae beyond the site of vaccination.

The clinical course of TTS following administration of the Janssen COVID-19
Vaccine shares features with autoimmune heparin-induced thrombocytopenia. In
individuals with suspected TTS, the use of heparin may be harmful and
alternative treatments may be needed.

Do not administer the Janssen COVID-19 Vaccine to individuals with a history of
thrombosis with thrombocytopenia following the Janssen COVID-19 Vaccine or any
other adenovirus-vectored COVID-19 vaccine.

This is not a complete list of all safety information for the Janssen COVID-19
Vaccine. Please read Emergency Use Authorization (EUA) Fact Sheet for Healthcare
Providers Administering Vaccine (Vaccination Providers) including full EUA
Prescribing Information available at
www.JanssenCOVID19Vaccine.com/EUA-factsheet.

AUTHORIZATION OF USE

The Janssen COVID-19 Vaccine is authorized for use under an Emergency Use
Authorization (EUA) for active immunization to prevent Coronavirus Disease 2019
(COVID-19) caused by severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) in individuals 18 years of age and older for whom other
FDA-authorized or approved COVID-19 vaccines are not accessible or clinically
appropriate, and in individuals 18 years of age and older who elect to receive
the Janssen COVID-19 Vaccine because they would otherwise not receive a COVID-19
vaccine.

* Primary vaccination regimen for the Janssen COVID-19 Vaccine is a single-dose
(0.5 mL).
* A single Janssen COVID-19 Vaccine booster dose (0.5 mL) may be administered
at least 2 months after the primary vaccination with the Janssen COVID-19
Vaccine.
* A single booster dose of the Janssen COVID-19 Vaccine (0.5 mL) may be
administered as a heterologous booster dose following completion of primary
vaccination with another authorized or approved COVID-19 vaccine. The dosing
interval for the heterologous booster dose is the same as that authorized for
a booster dose of the vaccine used for primary vaccination.

* FDA EUA Letter

* EUA Fact Sheet for HCPs

* EUA Fact Sheet for Recipients & Caregivers

Janssen.com

For medical inquiries or
product-related questions:

US Toll Free: 1-800-565-40081-800-565-4008
US Toll: 1-908-455-9922 1-908-455-9922

This site is published by Janssen Therapeutics, Division of Janssen Products,
LP, which is solely responsible for its contents. The material on this site is
intended only as informational or as an educational aid and it is not intended
to be taken as medical advice. The ultimate responsibility for patient care
resides with a healthcare professional.

This information is intended for use of healthcare providers in the United
States and its territories only. Laws, regulatory requirements, and medical
practices for pharmaceutical products vary from country to country. The
Prescribing Information included here may not be appropriate for use outside the
United States and its territories.

Third-party trademarks used herein are trademarks of their respective owners.

Cookie Policy

Cookies Settings
* Privacy Policy
* Do Not Sell or Share My Personal Information
* Legal Notice

EUA FACT SHEET FOR HEALTHCARE PROVIDERS ADMINISTERING VACCINE (VACCINATION
PROVIDERS) INCLUDING THE FULL EUA PRESCRIBING INFORMATION

PLEASE SELECT A LANGUAGE TO VIEW:

English

Spanish

EUA FACT SHEET FOR RECIPIENTS
AND CAREGIVERS

PLEASE SELECT A LANGUAGE TO VIEW:

English

Spanish

Additional Languages

FDA EUA LETTER FOR THE
JANSSEN COVID‑19 VACCINE

PLEASE SELECT A LANGUAGE TO VIEW:

English

Spanish

French

Portuguese

Chinese

Vietnamese

Tagalog

English
Accessibility Adjustments
Reset Settings Statement Hide Interface

Choose the right accessibility profile for you
OFF ON
Seizure Safe Profile Clear flashes & reduces color
This profile enables epileptic and seizure prone users to browse safely by
eliminating the risk of seizures that result from flashing or blinking
animations and risky color combinations.
OFF ON
Vision Impaired Profile Enhances website's visuals
This profile adjusts the website, so that it is accessible to the majority of
visual impairments such as Degrading Eyesight, Tunnel Vision, Cataract,
Glaucoma, and others.
OFF ON
ADHD Friendly Profile More focus & fewer distractions
This profile significantly reduces distractions, to help people with ADHD and
Neurodevelopmental disorders browse, read, and focus on the essential elements
of the website more easily.
OFF ON
Cognitive Disability Profile Assists with reading & focusing
This profile provides various assistive features to help users with cognitive
disabilities such as Autism, Dyslexia, CVA, and others, to focus on the
essential elements of the website more easily.
OFF ON
Keyboard Navigation (Motor) Use website with the keyboard
This profile enables motor-impaired persons to operate the website using the
keyboard Tab, Shift+Tab, and the Enter keys. Users can also use shortcuts such
as “M” (menus), “H” (headings), “F” (forms), “B” (buttons), and “G” (graphics)
to jump to specific elements.

Note: This profile prompts automatically for keyboard users.
OFF ON
Blind Users (Screen Reader) Optimize website for screen-readers
This profile adjusts the website to be compatible with screen-readers such as
JAWS, NVDA, VoiceOver, and TalkBack. A screen-reader is software that is
installed on the blind user’s computer and smartphone, and websites should
ensure compatibility with it.

Note: This profile prompts automatically to screen-readers.
Content Adjustments
Content Scaling
Default

Readable Font
Highlight Titles
Highlight Links
Text Magnifier
Adjust Font Sizing
Default

Align Center
Adjust Line Height
Default

Align Left
Adjust Letter Spacing
Default

Align Right
Color Adjustments
Dark Contrast
Light Contrast
High Contrast
High Saturation
Adjust Text Colors
Cancel
Monochrome
Adjust Title Colors
Cancel
Low Saturation
Adjust Background Colors
Cancel
Orientation Adjustments
Mute Sounds
Hide Images
Read Mode
Reading Guide
Useful Links
Select an option Home Header Footer Main Content
Stop Animations
Reading Mask
Highlight Hover
Highlight Focus
Big Black Cursor
Big White Cursor
HIDDEN_ADJUSTMENTS
Keyboard Navigation
Accessible Mode
Screen Reader Adjustments
Read Mode
Web Accessibility By
Learn More
Choose the Interface Language
English
Español
Deutsch
Português
Français
Italiano
עברית
繁體中文
Pусский
عربى
عربى
Nederlands
繁體中文
日本語
Polski
Türk
Accessibility StatementCompliance status

We firmly believe that the internet should be available and accessible to anyone
and are committed to providing a website that is accessible to the broadest
possible audience, regardless of ability.

To fulfill this, we aim to adhere as strictly as possible to the World Wide Web
Consortium’s (W3C) Web Content Accessibility Guidelines 2.1 (WCAG 2.1) at the AA
level. These guidelines explain how to make web content accessible to people
with a wide array of disabilities. Complying with those guidelines helps us
ensure that the website is accessible to blind people, people with motor
impairments, visual impairment, cognitive disabilities, and more.

This website utilizes various technologies that are meant to make it as
accessible as possible at all times. We utilize an accessibility interface that
allows persons with specific disabilities to adjust the website’s UI (user
interface) and design it to their personal needs.

Additionally, the website utilizes an AI-based application that runs in the
background and optimizes its accessibility level constantly. This application
remediates the website’s HTML, adapts its functionality and behavior for
screen-readers used by blind users, and for keyboard functions used by
individuals with motor impairments.

If you wish to contact the website’s owner please use the website's form

Screen-reader and keyboard navigation

Our website implements the ARIA attributes (Accessible Rich Internet
Applications) technique, alongside various behavioral changes, to ensure blind
users visiting with screen-readers can read, comprehend, and enjoy the website’s
functions. As soon as a user with a screen-reader enters your site, they
immediately receive a prompt to enter the Screen-Reader Profile so they can
browse and operate your site effectively. Here’s how our website covers some of
the most important screen-reader requirements:

1. Screen-reader optimization: we run a process that learns the website’s
components from top to bottom, to ensure ongoing compliance even when
updating the website. In this process, we provide screen-readers with
meaningful data using the ARIA set of attributes. For example, we provide
accurate form labels; descriptions for actionable icons (social media icons,
search icons, cart icons, etc.); validation guidance for form inputs;
element roles such as buttons, menus, modal dialogues (popups), and others.

Additionally, the background process scans all of the website’s images. It
provides an accurate and meaningful image-object-recognition-based
description as an ALT (alternate text) tag for images that are not
described. It will also extract texts embedded within the image using an OCR
(optical character recognition) technology. To turn on screen-reader
adjustments at any time, users need only to press the Alt+1 keyboard
combination. Screen-reader users also get automatic announcements to turn
the Screen-reader mode on as soon as they enter the website.

These adjustments are compatible with popular screen readers such as JAWS,
NVDA, VoiceOver, and TalkBack.

2. Keyboard navigation optimization: The background process also adjusts the
website’s HTML and adds various behaviors using JavaScript code to make the
website operable by the keyboard. This includes the ability to navigate the
website using the Tab and Shift+Tab keys, operate dropdowns with the arrow
keys, close them with Esc, trigger buttons and links using the Enter key,
navigate between radio and checkbox elements using the arrow keys, and fill
them in with the Spacebar or Enter key.

Additionally, keyboard users will find content-skip menus available at any
time by clicking Alt+2, or as the first element of the site while navigating
with the keyboard. The background process also handles triggered popups by
moving the keyboard focus towards them as soon as they appear, not allowing
the focus to drift outside.

Users can also use shortcuts such as “M” (menus), “H” (headings), “F”
(forms), “B” (buttons), and “G” (graphics) to jump to specific elements.

Disability profiles supported on our website
* Epilepsy Safe Profile: this profile enables people with epilepsy to safely
use the website by eliminating the risk of seizures resulting from flashing
or blinking animations and risky color combinations.
* Vision Impaired Profile: this profile adjusts the website so that it is
accessible to the majority of visual impairments such as Degrading Eyesight,
Tunnel Vision, Cataract, Glaucoma, and others.
* Cognitive Disability Profile: this profile provides various assistive
features to help users with cognitive disabilities such as Autism, Dyslexia,
CVA, and others, to focus on the essential elements more easily.
* ADHD Friendly Profile: this profile significantly reduces distractions and
noise to help people with ADHD, and Neurodevelopmental disorders browse,
read, and focus on the essential elements more easily.
* Blind Users Profile (Screen-readers): this profile adjusts the website to be
compatible with screen-readers such as JAWS, NVDA, VoiceOver, and TalkBack. A
screen-reader is installed on the blind user’s computer, and this site is
compatible with it.
* Keyboard Navigation Profile (Motor-Impaired): this profile enables
motor-impaired persons to operate the website using the keyboard Tab,
Shift+Tab, and the Enter keys. Users can also use shortcuts such as “M”
(menus), “H” (headings), “F” (forms), “B” (buttons), and “G” (graphics) to
jump to specific elements.

Additional UI, design, and readability adjustments
1. Font adjustments – users can increase and decrease its size, change its
family (type), adjust the spacing, alignment, line height, and more.
2. Color adjustments – users can select various color contrast profiles such as
light, dark, inverted, and monochrome. Additionally, users can swap color
schemes of titles, texts, and backgrounds with over seven different coloring
options.
3. Animations – epileptic users can stop all running animations with the click
of a button. Animations controlled by the interface include videos, GIFs,
and CSS flashing transitions.
4. Content highlighting – users can choose to emphasize essential elements such
as links and titles. They can also choose to highlight focused or hovered
elements only.
5. Audio muting – users with hearing devices may experience headaches or other
issues due to automatic audio playing. This option lets users mute the
entire website instantly.
6. Cognitive disorders – we utilize a search engine linked to Wikipedia and
Wiktionary, allowing people with cognitive disorders to decipher meanings of
phrases, initials, slang, and others.
7. Additional functions – we allow users to change cursor color and size, use a
printing mode, enable a virtual keyboard, and many other functions.

Assistive technology and browser compatibility

We aim to support as many browsers and assistive technologies as possible, so
our users can choose the best fitting tools for them, with as few limitations as
possible. Therefore, we have worked very hard to be able to support all major
systems that comprise over 95% of the user market share, including Google
Chrome, Mozilla Firefox, Apple Safari, Opera and Microsoft Edge, JAWS, and NVDA
(screen readers), both for Windows and MAC users.

Notes, comments, and feedback

Despite our very best efforts to allow anybody to adjust the website to their
needs, there may still be pages or sections that are not fully accessible, are
in the process of becoming accessible, or are lacking an adequate technological
solution to make them accessible. Still, we are continually improving our
accessibility, adding, updating, improving its options and features, and
developing and adopting new technologies. All this is meant to reach the optimal
level of accessibility following technological advancements. If you wish to
contact the website’s owner, please use the website's form

Hide Accessibility Interface? Please note: If you choose to hide the
accessibility interface, you won't be able to see it anymore, unless you clear
your browsing history and data. Are you sure that you wish to hide the
interface?
Accept Cancel

Continue

Processing the data, please give it a few seconds...
Press Alt+1 for screen-reader mode
SELECT IMPORTANT SAFETY INFORMATION

WARNING: THROMBOSIS WITH THROMBOCYTOPENIA SYNDROME

The Janssen COVID-19 Vaccine can cause thrombosis with thrombocytopenia syndrome
(TTS) which may be life-threatening.

TTS may involve thrombosis at unusual locations for a thrombus (i.e., cerebral
vein, visceral artery or vein, extremity artery, central artery or vein) or in
an extremity vein or pulmonary artery.

Among reported cases of TTS following administration of the Janssen COVID-19
Vaccine, symptoms began approximately one to two weeks after vaccination.

AUTHORIZATION OF USE

YOU ARE LEAVING JOHNSON & JOHNSON'S JANSSEN COVID‑19 VACCINE WEBSITE

You are being directed to a third-party website. Please note that this
third-party website is not controlled by Janssen or subject to our Privacy
Policy.

Thank you for visiting our site.

Continue Return

ESTÁ SALIENDO DEL SITIO WEB DE LA VACUNA CONTRA LA COVID‑19 DE JANSSEN DE
JOHNSON & JOHNSON.

Usted está siendo dirigido a un sitio web externo. Tenga en cuenta que este
sitio web externo no está controlado por Janssen ni está sujeto a nuestra
Política de privacidad.

Gracias por visitar nuestro sitio web.

CONTINUAR VOLVER

INFORMACIÓN NO DISPONIBLE EN ESPAÑOL

CONTINUAR VOLVER

YOU ARE LEAVING JOHNSON & JOHNSON'S JANSSEN COVID‑19 VACCINE WEBSITE

You are being directed to a third-party website. Please note that this
third-party website is not controlled by Janssen or subject to our Privacy
Policy.

Thank you for visiting our site.

Continue Return

ESTÁ SALIENDO DEL SITIO WEB DE LA VACUNA CONTRA LA COVID‑19 DE JANSSEN DE
JOHNSON & JOHNSON.

Usted está siendo dirigido a un sitio web externo. Tenga en cuenta que este
sitio web externo no está controlado por Janssen ni está sujeto a nuestra
Política de privacidad.

Gracias por visitar nuestro sitio web.

CONTINUAR VOLVER

INFORMACIÓN NO DISPONIBLE EN ESPAÑOL

CONTINUAR VOLVER
SELECT IMPORTANT SAFETY INFORMATION

WARNING: THROMBOSIS WITH THROMBOCYTOPENIA SYNDROME

The Janssen COVID-19 Vaccine can cause thrombosis with thrombocytopenia syndrome
(TTS) which may be life-threatening.

TTS may involve thrombosis at unusual locations for a thrombus (i.e., cerebral
vein, visceral artery or vein, extremity artery, central artery or vein) or in
an extremity vein or pulmonary artery.

Among reported cases of TTS following administration of the Janssen COVID-19
Vaccine, symptoms began approximately one to two weeks after vaccination.

AUTHORIZATION OF USE

YOU ARE LEAVING JOHNSON & JOHNSON'S JANSSEN COVID‑19 VACCINE WEBSITE

You are being directed to a third-party website. Please note that this
third-party website is not controlled by Janssen or subject to our Privacy
Policy.

Thank you for visiting our site.

Continue Return

ESTÁ SALIENDO DEL SITIO WEB DE LA VACUNA CONTRA LA COVID‑19 DE JANSSEN DE
JOHNSON & JOHNSON.

Usted está siendo dirigido a un sitio web externo. Tenga en cuenta que este
sitio web externo no está controlado por Janssen ni está sujeto a nuestra
Política de privacidad.

Gracias por visitar nuestro sitio web.

CONTINUAR VOLVER

INFORMACIÓN NO DISPONIBLE EN ESPAÑOL

CONTINUAR VOLVER

YOU ARE LEAVING JOHNSON & JOHNSON'S JANSSEN COVID‑19 VACCINE WEBSITE

You are being directed to a third-party website. Please note that this
third-party website is not controlled by Janssen or subject to our Privacy
Policy.

Thank you for visiting our site.

Continue Return

ESTÁ SALIENDO DEL SITIO WEB DE LA VACUNA CONTRA LA COVID‑19 DE JANSSEN DE
JOHNSON & JOHNSON.

Usted está siendo dirigido a un sitio web externo. Tenga en cuenta que este
sitio web externo no está controlado por Janssen ni está sujeto a nuestra
Política de privacidad.

Gracias por visitar nuestro sitio web.

CONTINUAR VOLVER

INFORMACIÓN NO DISPONIBLE EN ESPAÑOL

CONTINUAR VOLVER

WE VALUE YOUR PRIVACY

We want to give you the best experience, so we’d like to use cookies to tell us
how to improve our site, keep things relevant for you and enable social media
functions and ads. This information may also be used for the purposes of
personalized advertisements about products, programs and services which may be
considered sensitive in your state. You may visit our site’s privacy policy for
details about sensitive personal information, which may include, but are not
limited to health related information. For more information (including data
sharing with partners) or to adjust your preferences, see “Cookie Settings”.
Click “Accept” if you agree or “Reject” to use only necessary and performance
cookies.

Reject Accept
Cookies Settings

COOKIE PREFERENCE CENTER

When you visit any website, it may store or retrieve information on your
browser, mostly in the form of cookies. This information might be about you,
your preferences or your device and is mostly used to make the site work as you
expect it to. The information does not usually directly identify you, but it can
give you a more personalized web experience. This information may also be shared
with third parties. The cookies are set to expire when the information is no
longer needed or after a set maximum period. Because we respect your right to
privacy, you can choose not to allow some types of cookies. Click on the
different category headings to find out more (including the cookies used, their
purposes, their retention period and our partners) and change our default
settings. However, blocking some types of cookies may impact your experience of
the site and the services we are able to offer. You can read further information
on how we process your personal data and your privacy rights in our privacy
policy.
Allow All

MANAGE CONSENT PREFERENCES

STRICTLY NECESSARY COOKIES

Always Active

These cookies are necessary for the website to function and cannot be switched
off in our systems. They are usually only set in response to actions made by
you, which amount to a request for services, such as setting your privacy
preferences, logging in or filling in forms. You can set your browser to block
or alert you about these cookies, but some parts of the site will then not work.

Cookies Details‎

PERFORMANCE COOKIES

Always Active

These cookies allow us to count visits and traffic sources so we can measure and
improve the performance of our site. They help us to know which pages are the
most and least popular and see how visitors move around the site. If you do not
allow these cookies we will not know when you have visited our site, and will
not be able to monitor its performance. You can set your browser to block or
alert you about these cookies.

Cookies Details‎

TARGETING COOKIES

Targeting Cookies

These cookies may be set through our site by our advertising partners. They may
be used by those companies to build a profile of your interests and show you
relevant adverts on other sites. They do not store directly personal
information, but are based on uniquely identifying your browser and internet
device. If you do not allow these cookies, you will experience less targeted
advertising.

Cookies Details‎
Back Button

PERFORMANCE COOKIES

Search Icon
Filter Icon

Clear
checkbox label label
Apply Cancel
Consent Leg.Interest
checkbox label label
checkbox label label
checkbox label label

View Cookies

* Name
cookie name

Confirm My Choices

www.janssencovid19vaccine.com Open in urlscan Pro 2606:4700::6812:1c80 Public Scan

Form analysis 1 forms found in the DOM

POST #

Text Content

www.janssencovid19vaccine.com Open in urlscan Pro
2606:4700::6812:1c80 Public Scan

Form analysis
1 forms found in the DOM